Your Article Summary
See Latest ArticlesOctreotide Long-Acting Repeatable in Acromegaly: Achieving Optimal Control
The Endocrinologist, 06/19/09
Cook DM - In patients with acromegaly, octreotide LAR is traditionally used as postsurgical therapy in patients with persistent disease. Although surgery remains the first-line treatment option in patients with tumors likely to be completely resected, there is a growing consensus that octreotide LAR could be used as first-line therapy in select patients. Most patients initiating treatment with somatostatin analogs begin with octreotide LAR 20 mg every 28 days. On average, 60% of patients can safely achieve normal GH and insulin-like growth factor-I levels during octreotide LAR therapy, as well as experience significant reduction in pituitary tumor volume.
Related Articles
The Exon 3-Deleted Growth Hormone Receptor Is Associated with Better Response to Pegvisomant Therapy in Acromegaly
Journal of Clinical Endocrinology and Metabolism, 11/12/09
Relevance Score: 88%
The Exon-3 Deleted Growth Hormone Receptor Polymorphism Predisposes to Long-Term Complications of Acromegaly
Journal of Clinical Endocrinology and Metabolism, 11/12/09
Relevance Score: 87%
Discordant Nadir GH After Oral Glucose and IGF-I Levels on Treated Acromegaly: Refining the Biochemical Markers of Mild Disease Activity
Hormone and Metabolic Research, 10/06/09
Relevance Score: 87%
Prevalence of mental disorders in acromegaly: a cross-sectional study in 81 acromegalic patients
Clinical Endocrinology, 10/15/09
Relevance Score: 85%
ACTH Deficiency, Higher Doses of Hydrocortisone Replacement, and Radiotherapy Are Independent Predictors of Mortality in Patients with Acromegaly
Journal of Clinical Endocrinology and Metabolism, 10/14/09
Relevance Score: 85%
Today in Adrenal Glands...keeping you current
Receive free subspecialty "5-minute updates" via email
Diagnosis of Adrenal Insufficiency Using the GHRP-6 Test: Comparison with the Insulin Tolerance Test in Patients with Hypothalamic-Pituitary-Adrenal Disease
Hormone and Metabolic Research, 12/02/09
Energy-based hemostatic devices in laparoscopic adrenalectomy
Langenbeck's Archives of Surgery, 12/02/09
Isocitrate Dehydrogenase Mutations Are Rare in Pheochromocytomas and Paragangliomas
Journal of Clinical Endocrinology and Metabolism, 11/25/09
Today in Endocrine Oncology...keeping you current
Receive free subspecialty "5-minute updates" via email
Oncocytic versus mitochondrion-rich follicular thyroid tumours: should we make a difference
Histopathology, 12/04/09
CD98 expression is decreased in papillary carcinoma of the thyroid and Hashimotos thyroiditis
Histopathology, 12/04/09
Absence of Peritumoral Fibrosis or Inflammatory Infiltrate May Be Related to Clinical Progression of Papillary Thyroid Microcarcinoma
International Journal of Surgical Pathology, 12/03/09
Today in Neuroendocrinology...keeping you current
Receive free subspecialty "5-minute updates" via email
Davalintide (AC2307), a novel amylin-mimetic peptide: enhanced pharmacological properties over native amylin to reduce food intake and body weight
International Journal of Obesity, 11/30/09
Familial Cervical Paragangliomas with Lymph Node Metastasis Expressing Somatostatin Receptor Type 2A
Endocrine Pathology, 11/30/09
Neuroendocrine carcinomas arising in solid-organ transplant recipients: rare but aggressive malignancies
Oncology (Karger), 11/25/09
Today in Pharmacology/kinetics...keeping you current
Receive free subspecialty "5-minute updates" via email
The association between thiazolidinediones and hospitalisation for fracture in type 2 diabetic patients: a Taiwanese population-based nested case-control study
Diabetologia - Clinical and Experimental Diabetes and Metabolism, 12/04/09
Effect of minodronic acid hydrate on hip geometry in Japanese women with postmenopausal osteoporosis
Journal of Bone and Mineral Metabolism, 12/04/09
Myxedema Coma Associated with Combination Aripiprazole and Sertraline Therapy
Annals of Pharmacotherapy, 12/03/09